Q&A Zealand Pharma 2019-12-03

	3/12 16:10 af Emmanuel Dulac	Zealand Pharma has made impressive progress so far this year! We were thrilled with the results from the pediatric study in the Phase 3 clinical program for dasiglucagon HypoPal, which concluded the clinical program and we have full focus on preparing the NDA to submit early next year...
	3/12 16:09 af Helge Larsen/PI-redaktør	Can you please give us a short-term update on key figures and important events for Q3.
	3/12 16:08 af Helge Larsen/PI-redaktør	Good afternoon, Emmanuel Dulac and welcome to Q&A with us here on ProInvestor.com. We are very happy to have you with us today - ready to answer a wide variety of questions from our investors.
	3/12 16:08 af Emmanuel Dulac	I am finally online now
	3/12 16:07 af Helge Larsen/PI-redaktør	Great.
	3/12 16:07 af Emmanuel Dulac	Hello
	3/12 15:58 af Helge Larsen/PI-redaktør	Emmanuel Dulac, are you online?
	3/12 15:04 af Helge Larsen/PI-redaktør	Q&A starter i dag kl. 16.